The state of prostate MRI in 2013

ONCOLOGY (United States)

Volumn 27, Issue 4, 2013, Pages

  Gupta, Rajan T ^a   Kauffman, Christopher R ^a   Polascik, Thomas J ^a   Taneja, Samir S ^b   Rosenkrantz, Andrew B ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD FLOW; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INVASION; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMPUTER; COMPUTER PROGRAM; CONCENTRATION RESPONSE; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; INTERMETHOD COMPARISON; MAGNETIC FIELD; MALE GENITAL SYSTEM EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SIZE; PROTEIN BLOOD LEVEL; QUALITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SEMINAL VESICLE; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; SIGNAL TRANSDUCTION; STANDARDIZATION; T2 WEIGHTED IMAGING; TISSUE STRUCTURE; TREATMENT PLANNING; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 84876266426     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Damico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-74.
2. Eifler JB, Feng Z, Lin BM, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 2013;111:22-9.
3. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766-71.
4. Yacoub JH, Verma S, Moulton JS, et al. Imaging-guided prostate biopsy: conventional and emerging techniques. Radiographics. 2012;32:819-37.
5. Mufarrij P, Sankin A, Godoy G, et al. Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy. Urology. 2010;76:689-92.
6. Onik G, Miessau M, Bostwick DG. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol. 2009;27:4321-6.
7. Steyn JH, Smith FW. Nuclear magnetic resonance imaging of the prostate. Br J Urol. 1982;54:726-8.
8. Chang KJ, Kamel IR, Macura KJ, et al. 3.0-T MR imaging of the abdomen: comparison with 1.5 T. Radiographics. 2008;28:1983-98.
9. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22:746-57.
10. Heijmink SWTPJ, Fütterer JJ, Hambrock T, et al. Prostate cancer: body-array versus endorectal coil MR imaging at 3 Tcomparison of image quality, localization, and staging performance. Radiology. 2007;244:184-95.
11. Kim BS, Kim T-H, Kwon TG, et al. Comparison of pelvic phased-array versus endorectal coil magnetic resonance imaging at 3 Tesla for local staging of prostate cancer. Yonsei Med J. 2012;53:550-6.
12. Vargas HA, Akin O, Franiel T, et al. Normal central zone of the prostate and central zone involvement by prostate cancer: clinical and MR imaging implications. Radiology. 2012;262:894-902.
13. Turkbey B, Albert PS, Kurdziel K, et al. Imaging localized prostate cancer: current approaches and new developments. Am J Roentgenol. 2009;192:1471-80.
14. Turkbey B, Pinto P, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detectionhistopathologic correlation. Radiology. 2010; 255:89-99.
15. Turkbey B, Mani H, Shah V, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol. 2011;186:1818-24.
16. Delongchamps NB, Beuvon F, Eiss D, et al. Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer. Prostate Cancer Prostatic Dis. 2011;14:232-7.
17. Tamada T, Sone T, Higashi H, et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. Am J Roentgenol. 2011;197:664-70.
18. Isebaert S, Van den Bergh L, Haustermans K, et al. Multiparametric MRI for prostate cancer localization in correlation to whole-mount histopathology. J Magn Reson Imaging. 2012 Nov 21. [Epub ahead of print]
19. Chen M, Dang H-D, Wang J-Y, et al. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol. 2008;49:602-10.
20. Tan CH, Wei W, Johnson V, et al. Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis. Am J Roentgenol. 2012;199:822-9.
21. Koh D-M, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am J Roentgenol. 2007;188:1622-35.
22. Wu L-M, Xu J-R, Ye Y-Q, et al. The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: a systematic review and meta-analysis. Am J Roentgenol. 2012;199:103-10.
23. Delongchamps NB, Rouanne M, Flam T, et al. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int. 2011; 107:1411-8.
24. Woodfield C, Tung G, Grand DJ, et al. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. Am J Roentgenol. 2010;194:W316-W322.
25. Verma S, Rajesh A, Morales H, et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. Am J Roentgenol. 2011;
26. Hambrock T, Somford DM, Huisman HJ, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology. 2011;259:453-61.
27. Vargas HA, Akin O, Franiel T, et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology. 2011;259:775-84.
28. Pang Y, Turkbey B, Bernardo M, et al. Intravoxel incoherent motion MR imaging for prostate cancer: An evaluation of perfusion fraction and diffusion coefficient derived from different b-value combinations. Magn Reson Med. 2012;69:553-62.
29. Thörmer G, Otto J, Reiss-Zimmermann M, et al. Diagnostic value of ADC in patients with prostate cancer: influence of the choice of b values. Eur Radiol. 2012;22:1820-8.
30. Litjens GJS, Hambrock T, Hulsbergen-van de Kaa C, et al. Interpatient variation in normal peripheral zone apparent diffusion coefficient: effect on the prediction of prostate cancer aggressiveness. Radiology. 2012;265:260-6.
31. Verma S, Turkbey B, Muradyan N, et al. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. Am J Roentgenol. 2012; 198:1277-88.
32. Ocak I, Bernardo M, Metzger G, et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Am J Roentgenol. 2007;189:849.
33. Kim JK, Hong SS, Choi YJ, et al. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging. 2005;22:639-46.
34. Girouin N, Mège-Lechevallier F, Tonina Senes A, et al. Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: Is it reasonable? Eur Radiol. 2007;17:1498-509.
35. Low RN, Fuller DB, Muradyan N. Dynamic gadolinium-enhanced perfusion MRI of prostate cancer: assessment of response to hypofractionated robotic stereotactic body radiation therapy. Am J Roentgenol. 2011;197:907-15.
36. Verma S, Rajesh A, Fütterer JJ, et al. Prostate MRI and 3D MR spectroscopy: how we do it. Am J Roentgenol. 2010;194:1414-26.
37. Awwad HM, Geisel J, Obeid R. The role of choline in prostate cancer. Clin Biochem. 2012;45:1548-53.
38. Weinreb JC, Blume JD, Coakley F V, et al. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomyresults of ACRIN prospective multi-institutional clinicopathologic study. Radiology. 2009;251:122-33.
39. Riches SF, Payne GS, Morgan VA, et al. MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. Am J Roentgenol. 2009;193:1583-91.
40. Langer DL, Van der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2sparse versus dense cancers. Radiology. 2008;249:900-8.
41. Noguchi M, Stamey T, McNeal JE, et al. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol. 2003;170:459-63.
42. Wise AM, Stamey T, McNeal JE, et al. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology. 2002; 60:264-9.
43. Turkbey B, Mani H, Aras O, et al. Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol. 2012;188:1157-63.
44. Kobus T, Vos PC, Hambrock T, et al. Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T. Radiology. 2012;265:457-67.
45. Hambrock T, Hoeks C, Hulsbergen-van de Kaa C, et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol. 2012;61:177-84.
46. Turkbey B, Shah VP, Pang Y, et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology. 2011;258:488-95.
47. Oto A, Yang C, Kayhan A, et al. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. Am J Roentgenol. 2011;197:1382-90.
48. Augustin H, Fritz G, Ehammer T, et al. Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the Partin tables. Acta Radiol. 2009;50:562-9.
49. Renard-Penna R, Rouprêt M, Comperat E, et al. Accuracy of high resolution (1.5 Tesla) pelvic phased array magnetic resonance imaging (MRI) in staging prostate cancer in candidates for radical prostatectomy: results from a prospective study. Urol Oncol. 2011 Jul 18. [Epub ahead of print]
50. Nishida K, Yuen S, Kamoi K, et al. Incremental value of T2-weighted and diffusion-weighted MRI for prediction of biochemical recurrence after radical prostatectomy in clinically localized prostate cancer. Acta Radiol. 2011;52:120-6.
51. Pinto F, Totaro A, Palermo G, et al. Imaging in prostate cancer staging: present role and future perspectives. Urol Int. 2012;88:125-36.
52. Rosenkrantz AB, Scionti SM, Mendrinos S, et al. Role of MRI in minimally invasive focal ablative therapy for prostate cancer. Am J Roentgenol. 2011; 197:W90-6.
53. Yerram NK, Volkin D, Turkbey B, et al. Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU Int. 2012;110(11 Pt B):E783-8.
54. Rosenkrantz AB, Deng F-M, Kim S, et al. Prostate cancer: multiparametric MRI for index lesion localizationa multiple-reader study. Am J Roentgenol. 2012;199:830-7.
55. Ahmed HU, Hindley RG, Dickinson L, et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol. 2012;13:622-32.
56. Ahmed HU, Freeman A, Kirkham A, et al. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol. 2011;185:1246-54.
57. De la Rosette J, Ahmed H, Barentsz J, et al. Focal therapy in prostate cancer-report from a consensus panel. J Endourol. 2010;24:775-80.
58. McClure TD, Margolis DJA, Reiter RE, et al. Use of MR imaging to determine preservation of the neurovascular bundles at robotic-assisted laparoscopic prostatectomy. Radiology. 2012;262:874-83.
59. Muglia VF, Westphalen AC, Wang ZJ, et al. Endorectal MRI of prostate cancer: incremental prognostic importance of gross locally advanced disease. Am J Roentgenol. 2011;197:1369-74.
60. Pinkawa M, Schoth F, Böhmer D, et al. Current standards and future directions for prostate cancer radiation therapy. Expert Rev Anticancer Ther. 2013;13:75-88.
61. Groenendaal G, Van den Berg CAT, Korporaal JG, et al. Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients. Radiother Oncol. 2010;95:185-90.
62. Tamada T, Sone T, Jo Y, et al. Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors. Am J Roentgenol. 2011;197: 408-14.
63. Westphalen AC, Reed GD, Vinh PP, et al. Multiparametric 3T endorectal MRI after external beam radiation therapy for prostate cancer. J Magn Reson Imaging. 2012;36:430-7.
64. Morgan VA, Riches SF, Giles S, et al. Diffusion-weighted MRI for locally recurrent prostate cancer after external beam radiotherapy. Am J Roentgenol. 2012;198:596-602.
65. Westphalen AC, Coakley FV, Roach M, et al. Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection. Radiology. 2010;256:485-92.
66. Nguyen PL, Chen M-H, Zhang Y, et al. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J Urol. 2012;188:1151-6.
67. Jouyaux F, De Crevoisier R, Manens J-P, et al. High dose for prostate irradiation with image guided radiotherapy: contribution of intensity modulation arctherapy. Cancer Radiother. 2010;14:679-89.
68. Panebianco V, Barchetti F, Sciarra A, et al. Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol. 2013. [Epub ahead of print]